GlassScriptPhysician profile
Pampana Gowd
NPI 1043499460
$11,321.41
in general payments reported to CMS, 2019-2025
26 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $136 · 2021: $1,571 · 2022: $3,587 · 2023: $2,244 · 2024: $1,769 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,998 · Food and Beverage: $2,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,998.37 |
| Food and Beverage | $2,711.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,722.67 | 2022-2025 | Corevalve Evolut R, Spiderfx, Selectsecure |
| Abbott Laboratories | $3,455.83 | 2019-2025 | Aveir, Cardiomems, Mitraclip |
| Edwards Lifesciences Corporation | $972.35 | 2022-2025 | Pascal |
| Boston Scientific Corporation | $327.77 | 2021-2022 | |
| Astellas Pharma US INC | $179.98 | 2019-2020 | |
| Penumbra, INC. | $176.50 | 2022-2025 | Indigo System, Penumbra System |
| Cardiovascular Systems INC. | $154.83 | 2021-2022 | |
| Abiomed | $153.12 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $140.00 | 2021 | |
| W. L. Gore & Associates, INC. | $119.17 | 2023 | Gore Cardioform Septal Occluder |
| Amgen INC. | $115.72 | 2019-2024 | Repatha |
| Haemonetics Corporation | $101.56 | 2023 | |
| Angiodynamics, INC. | $91.39 | 2025 | Angiovac |
| Pfizer INC. | $73.67 | 2019-2024 | |
| Philips North America LLC | $71.74 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $71.23 | 2021 | |
| Cardiva Medical, INC. | $70.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $64.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.41 | 2019-2022 | |
| Scpharmaceuticals INC. | $48.07 | 2024 | |
| Merck Sharp & Dohme LLC | $41.57 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.24 | 2019 | |
| Reflow Medical INC | $20.59 | 2025 | |
| Cook Medical LLC | $19.66 | 2021 | |
| Impulse Dynamics (USA) INC. | $18.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pampana Gowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.